CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis
Authors:
Open Access
- 10 October 2022
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 60 (1) , 36-50
Abstract
Several biomarkers from multiple sclerosis (MS) patients’ biological fluids have been considered to support diagnosis, predict disease course, and evaluate treatment response. In this study, we assessed the CSF concentration of selected molecules implicated in the MS pathological process. To investigate the diagnostic and prognostic significance of CSF concentration of target candidate biomarkers in both relapsing (RMS,n = 107) and progressive (PMS,n = 18) MS patients and in other inflammatory (OIND,n = 10) and non-inflammatory (ONIND,n = 15) neurological disorders. We measured the CSF concentration of APRIL, BAFF, CHI3L1, CCL-2, CXCL-8, CXCL-10, CXCL-12, CXCL-13 through a Luminex Assay. MS patients were prospectively evaluated, and clinical and radiological activity were recorded. CHI3L1 and CXCL13 CSF levels were significantly higher in both MS groups compared to control groups, while CCL2, BAFF, and APRIL concentrations were lower in RMS patients compared to PMS and OIND. Considering RMS patients with a single demyelinating event, higher concentrations of CHI3L1, CXCL10, CXCL12, and CXCL13 were recorded in patients who converted to clinically defined MS(CDMS). RMS patients in the CXCL13 and CHI3L1 high concentration group had a significantly higher risk of relapse (HR 12.61 and 4.57), MRI activity (HR 7.04 and 2.46), and of any evidence of disease activity (HR 12.13 and 2.90) during follow-up. CSF CXCL13 and CHI3L1 levels represent very good prognostic biomarkers in RMS patients, and therefore can be helpful in the treatment choice. Higher CSF concentrations of neuro-inflammatory biomarkers were associated with a higher risk of conversion to CDMS in patients with a first clinical demyelinating event. Differential CSF BAFF and APRIL levels between RMS and PMS suggest a different modulation of B-cells pathways in the different phases of the disease.Keywords
Funding Information
- Università Cattolica del Sacro Cuore
This publication has 64 references indexed in Scilit:
- Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid BiomarkersPLOS ONE, 2013
- Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple SclerosisPLOS ONE, 2013
- Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trialJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosisBrain, 2010
- In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseasesJournal of Neuroinflammation, 2010
- A consensus protocol for the standardization of cerebrospinal fluid collection and biobankingNeurology, 2009
- Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patientsAnnals of Neurology, 2006
- Modulating CCR2 and CCL2 at the blood–brain barrier: relevance for multiple sclerosis pathogenesisBrain, 2005
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983